Isoproterenol regulates tumour necrosis factor, interleukin‐10, interleukin‐6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia
Open Access
- 1 January 1997
- journal article
- Published by Wiley in Immunology
- Vol. 90 (1) , 95-100
- https://doi.org/10.1046/j.1365-2567.1997.00137.x
Abstract
Pro‐inflammatory cytokines, such as tumour necrosis factor (TNF) and free radicals, such as nitric oxide (NO), are mediators of endotoxaemia. Catecholamines are in clinical use to treat the haemodynamic consequences of severe septic shock. Beta‐adrenergic agonists exert many of their effects by elevation of intracellular cyclic AMP (cAMP) concentration. Cyclic AMP can modulate endotoxin‐induced cytokine and NO production. Here we investigate the effect of isoproterenol pretreatment on the cytokine and NO production induced by bacterial lipopolysaccharide (LPS, 4–10 mg/kg). Pretreatment with isoproterenol (10 mg/kg) blunted the LPS‐induced TNF response, increased the LPS‐induced formation of interleukin‐10 and interleukin‐6 and reduced the LPS‐induced production of NO in conscious mice. In anaesthetized rats, pretreatment with isoproterenol prevented the LPS‐induced suppression of vascular contractility to norepinephrine in the thoracic aorta ex vivo. The hyporeactivity is due to expression of the inducible isoform of NO synthase (iNOS) and was restored by in vitro administration of NG‐methyl‐l‐arginine (l‐NMA), an inhibitor of NO synthase. However, l‐NMA did not alter vascular contractility in control vessels or in rings taken from the LPS‐treated rats pretreated with isoproterenol. Our findings suggest that, in addition to its haemodynamic actions, isoproterenol may also exert beneficial effects by modulating the endotoxin‐induced inflammatory response.Keywords
This publication has 29 references indexed in Scilit:
- Peroxynitrite‐mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia‐reperfusion injuryFEBS Letters, 1995
- Modulation of lipopolysaccharide-induced tumor necrosis factor-α production by selective α- and β-adrenergic drugs in miceJournal of Neuroimmunology, 1995
- Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugsInternational Immunology, 1995
- Differential effect of selective block of α2-adrenoreceptors on plasma levels of tumour necrosis factor-α, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in miceJournal of Endocrinology, 1995
- Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2.The Journal of Experimental Medicine, 1994
- Differential regulatory effects of adenosine on cytokine release by activated human monocytes.The Journal of Immunology, 1994
- NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs.1994
- Activation of Soluble Guanylyl Cyclase by a Factor Other Than Nitric Oxide or Carbon Monoxide Contributes to the Vascular Hyporeactivity to Vasoconstrictor Agents in the Aorta of Rats Treated with EndotoxinBiochemical and Biophysical Research Communications, 1994
- Effects of a nitric oxide synthase inhibitor in humans with septic shockCardiovascular Research, 1994
- Cyclic AMP-elevating agents induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Synergism with the induction elicited by inflammatory cytokines.Journal of Biological Chemistry, 1993